Recent Updates
Recently added Catalysts
Specialist biotech fund · SEC 13F

DAFNA Capital Management 13F Holdings (Q2 2026)

According to its SEC 13F filed on Aug 14, 2026, DAFNA Capital Management reported 88 long positions worth $524M as of Jun 30, 2026. RVMD is 20.1% of the portfolio and the top 10 holdings are 56%. Against Q1 2026 it opened 14 new positions, added to 18, trimmed 28 and exited 9. 19 holdings have a dated FDA decision or data readout in the next 90 days, and 33 more expect one in a stated window such as "H2 2026".

Data as of Jun 30, 2026SEC 13F filed Aug 14, 2026Next filing (Q3 2026) due Nov 16, 2026Value as filed; options at underlying sharesLong positions only
Market Value$ 524.36 M13F value, as filed
QoQ Changes19.28 %13F value vs the previous quarter
Holdings88 88 stocks · 0 option positions
PeriodQ2 202613F reporting quarter
Holdings in Top 20 % top 10: 56% of the portfolio
Activity vs Q1 202614 new18 added · 28 trimmed · 9 exits
Catalysts ahead19dated in 90 days · +33 in a stated window

Catalysts ahead in this portfolio

Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval

Nov 3, 2026PRQRPre-clinical data presentation: AX-0811PoA 4%
Nov 4, 2026PLRXPhase 1a/1b data presentation: PLN-101095PoA 12%

17 more with a subscription

What changed vs Q1 2026

KYMRKymera$3M
ANLAdlai Nortye Ltd. American Depositary Shares$3M

Full lists with a subscription

Portfolio over time

13F value by quarter, Q1 2021 to Q2 2026

Q1 2021: $421MQ2 2026: $524M

By company stage (share of value)

Clinical 43%Commercial 42%Other 15%

Holdings

Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.

Showing 6 Stocks Out Of 88. Click On The Tickers For More Details
Stock Company Name Shares Held Market Value % of Portfolio QoQ Change Position Change Also Held By Stage Next Catalyst
QTTB
QTTB
Q32 BIO INC
32.90 K
419.10 K
0.1
New
Clinical
None in 90 days
MBX
MBX
MBX BIOSCIENCES INC
11.81 K
651.86 K
0.1
Trimmed -93%
Clinical
Expected 2026
Phase 2a data readout
TNDM
TNDM
TANDEM DIABETES CARE INC
355.21 K
5.36 M
1
Unchanged
—
None in 90 days
NVCT
NVCT
NUVECTIS PHARMA INC
20.00 K
367.80 K
0.1
New
Clinical
Expected Q4 2026
IND Submission
BHVN
BHVN
BIOHAVEN LTD
137.59 K
2.05 M
0.4
Trimmed -84%
Clinical
Nov 19, 2026
Phase 1 data presentation
FHTX
FHTX
FOGHORN THERAPEUTICS INC
111.86 K
545.87 K
0.1
Unchanged
Clinical
Expected 2026
IND Submission

Top 20 Holdings

Size = share of the portfolio. Option positions show CALL or PUT.

Who else owns these stocks?

All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.

Open All Stock Holdings ›

Questions about DAFNA Capital Management's 13F

What does DAFNA Capital Management own?

88 stocks worth $524M at Jun 30, 2026, as reported in its 13F, led by RVMD (20.1% of the portfolio). The full list is in the Holdings table above.

What did it buy and sell last quarter?

Against Q1 2026: 14 new positions, 18 increases, 28 reductions and 9 full exits, from its 13F filings.

How current is this data?

13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q3 2026) is due Nov 16, 2026.

Why are some positions labelled CALL or PUT?

Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.

Source: SEC EDGAR Form 13F-HR filed by DAFNA Capital Management LLC, accession 0001389933-26-000006, filed Aug 14, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.